6 results about "Allergic dermatitis" patented technology

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating skin tinea, allergic dermatitis and acne, and relates to the field of pharmaceutical preparations, the extraction rate of gallic acid and ethyl gallate contained in total tannin in fructus chebulae flesh, fructus terminaliae billericae flesh and fructus chebulae immaturus is improved through an enzymolysis method, and the transfer rate of effective components of quercetin is improved through a boiling granulation technology; therefore, the effect of treating psoriasis of the composition is improved. By adopting a boiling granulation technology, the technical problems of long preparation period and high cost in the prior art are solved. The release speed of aloe in intestinal tracts is controlled by adopting a slow release technology, and the upper and lower limit content range of barbaloin is controlled to reduce the occurrence rate of adverse reactions of the composition. Meanwhile, butyl hydroxy anisd (BHA), butylated hydroxytoluene (BHT) and a citric acid system are adopted, so that the problems of PEO skeleton degradation, out-of-control drug release behavior and insufficient main drug stability of the barbaloin-PEO sustained release preparation are solved.

The present application relates to the use of substituted indazoles for treatment and / or prophylaxis of allergic and / or inflammatory diseases in animals, especially for treatment and / or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.

The present invention relates to a collar for non-human animals, preferably for companion animals, comprising a polymeric matrix and a lipid extract comprising sphingomyelins. It also refers to the collar for use as a medicine, particularly for use as an adjuvant and for use in the treatment or prevention of atopic dermatitis or allergic dermatitis, as well as in restoring the integrity of the skin during or after an atopic dermatitis or an allergic dermatitis, increasing the hydration and flexibility of the skin, facilitating skin regeneration or reducing itching of the skin.

The application belongs to the technical field of medicine, and discloses skin health antipruritic liquid, which comprises raw material components: angelica, cortex moutan, white alum, forsythia, schizonepeta, baizhi, humulus, zanthoxylum, lotus house, artemisia leaf, duckweed, alkanna, aloe, honeycomb, polygonatum, stemona, sophora, fly Yang grass, cortex periplocae, melaleuca, ophiorrhiza, white milkweed, gallic, spilanthes, kochia, taraxacum, clematis, xuchangqing, biota, radix falcaliae, radix pterostupiae, red plate, snake skin, wind-preventing plant, hollyhock, oak flower, oak, radix scrophulariae, radix paeoniae, radix bupleuri, radix scrophulariae, radix paeoniae, radix scrophulariae, radix paeoniae, radix scrophulariae, borage, borax, the application has multiple effects of clearing heat and cooling blood, sterilizing and resisting inflammation, removing dampness and relieving itching, removing toxicity and resolving mass, etc., can improve or treat various skin problems such as eczema, herpes, allergic dermatitis, tinea pedis, hemorrhoids, acne, psoriasis and skin itching, and is suitable for a wide range of scenes; the process combination of crushing, screening, specific proportion mixing, fermentation, multiple filtration and accurate concentration ensures that the active ingredients in the raw materials are fully extracted and purified, avoids the loss of effective components, improves the curative effect intensity of unit volume of liquid medicine, and has quick effect after spraying, which is beneficial to actual application and operation.